Salicylic Acid

Salicylic Acid

SCHEMBL515322

CC(O)C(=O)O.N.N.O=C(O)c1ccccc1O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHE

The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.69
HPGD P15428 8/20 0.69
KDM4E B2RXH2 8/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
CA12 O43570 1/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69
HMGB1 P09429 1/20 0.69
CA4 P22748 1/20 0.69
CA6 P23280 1/20 0.69
CA7 P43166 1/20 0.69
CA9 Q16790 1/20 0.69
NAPRT Q6XQN6 1/20 0.69
CA14 Q9ULX7 1/20 0.69
HSD17B10 Q99714 5/20 0.49
LMNA P02545 5/20 0.49
ALOX15 P16050 2/20 0.48
ALOX12 P18054 1/20 0.46
TSHR P16473 2/20 0.46
G6PD P11413 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicylic Acid SCHEMBL515324 1.00 ALDH1A1 (0.69) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL8742102 0.98 ALDH1A1 (0.72) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL31251472 0.98 ALDH1A1 (0.72) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL27871001 0.90 ALDH1A1 (0.78) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL15568422 0.90 ALDH1A1 (0.78) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL27657568 0.90 KDM4E (0.60) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL27880804 0.88 ALDH1A1 (0.75) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL1835793 0.86 ALDH1A1 (0.72) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Phthalic Acid SCHEMBL28654022 0.86 ALDH1A1 (0.67) ALDH1A1HPGDKDM4ESMN1; SMN2CA12
Salicylic Acid SCHEMBL1062720 0.85 ALDH1A1 (0.95) ALDH1A1HPGDKDM4ESMN1; SMN2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2498746-B1 SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES UNILEVER PLC NO 41424 (GB) 2016-08-24 EP disclosed
EP-2598110-B1 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES UNILEVER PLC (GB) 2015-09-02 EP disclosed
EP-2598111-B1 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED DIAMINES UNILEVER PLC (GB) 2015-03-25 EP disclosed
US-8476251-B2 Skin care compositions comprising substituted diamines CONOPCO, INC. (US) 2013-07-02 US disclosed
EP-2598110-A2 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES Unilever PLC (GB) 2013-06-05 EP disclosed
EP-2598111-A2 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED DIAMINES Unilever PLC (GB) 2013-06-05 EP disclosed
US-8309064-B2 Skin care compositions comprising phenoxyalkyl amines CONOPCO, INC. (US) 2012-11-13 US disclosed
US-8293218-B2 Skin care compositions comprising substituted monoamines CONOPCO, INC. (US) 2012-10-23 US disclosed
EP-2498746-A2 SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) 2012-09-19 EP disclosed
US-20120027699-A1 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES CONOPCO, INC., D/B/A UNILEVER (US) 2012-02-02 US disclosed
US-20120027700-A1 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED DIAMINES CONOPCO, INC., D/B/A UNILEVER (US) 2012-02-02 US disclosed
WO-2012013417-A2 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED DIAMINES UNILEVER PLC (GB) 2012-02-02 WO disclosed
WO-2012013418-A2 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES UNILEVER PLC (GB) 2012-02-02 WO disclosed
WO-2011054804-A2 SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES UNILEVER PLC (GB) 2011-05-12 WO disclosed
US-20110110870-A1 SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES CONOPCO, INC., D/B/A UNILEVER (US) 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027699-A1 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES TYR, CUTA, MAOA ALDH1A1 606/4885HPGD 2211/4885KDM4E 331/4885
US-20110110870-A1 SKIN CARE COMPOSITIONS COMPRISING PHENOXYALKYL AMINES CUTA, TYR, FLNA ALDH1A1 1317/4885HPGD 2000/4885KDM4E 89/4885
US-20120027700-A1 SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED DIAMINES CUTA, TYR, DSG1 ALDH1A1 885/4885HPGD 1505/4885KDM4E 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.